Article 1
Open ↗Thermally treated garlic juice is approved as an active substance for use in biocidal products of product-type 19, subject to the conditions set out in the Annex.
Source
Commission Implementing Regulation (EU) 2024/893 of 22 March 2024 approving thermally treated garlic juice as an existing active substance for use in biocidal products of product-type 19 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Commission Implementing Regulation (EU) 2024/893 of 22 March 2024 approving thermally treated garlic juice as an existing active substance for use in biocidal products of product-type 19 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗
Article 2
Open ↗This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .
Supplementary provisions
ANNEXSupplementary provisions
Open ↗ANNEX Common Name IUPAC Name Identification Numbers Minimum degree of purity of the active substance ( 1 ) Date of approval Expiry date of approval Product type Specific conditions Thermally treated garlic juice Thermally treated garlic juice EC No: — CAS No: — Thermally treated garlic juice is an unknown or variable composition, complex reaction products or of biological materials (UVCB) substance. The purity is 100 % weight per weight (w/w). It is derived from garlic juice that is thermally treated and has food grade quality. In addition, thermally treated garlic juice is characterised by four marker compounds: diallyl sulfide (DAS1), diallyl disulfide (DAS2), diallyl trisulfide (DAS3) and diallyl tetrasulfide (DAS4). 1 July 2025 30 June 2035 19 The authorisation of biocidal products is subject to the following condition: the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance. ( 1 ) The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.
Other acts of the same type
Commission Implementing Regulation (EU) 2025/142 of 29 January 2025 concerning the authorisation of a preparation of 6-phytase produced with Trichoderma reesei CBS 126897 as a feed additive for fin fish (holder of authorisation: AB Enzymes Finland Oy)Commission Implementing Regulation (EU) 2025/143 of 29 January 2025 concerning the authorisation of L-isoleucine produced with Corynebacterium glutamicum CGMCC 20437 as a feed additive for all animal speciesCommission Regulation (EU) 2025/146 of 29 January 2025 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for zoxamide in or on certain productsCommission Regulation (EU) 2025/147 of 29 January 2025 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council as regards the removal of the flavouring substance 4-Methyl-2-phenylpent-2-enal (FL No 05.100) from the Union listCommission Implementing Regulation (EU) 2025/148 of 29 January 2025 concerning the renewal of the authorisation of a preparation of Enterococcus lactis NCIMB 11181 as a feed additive for calves for rearing and for fattening and weaned piglets (holder of authorisation: Chr. Hansen A/S) and repealing Implementing Regulation (EU) No 797/2013Commission Implementing Regulation (EU) 2025/150 of 29 January 2025 renewing the approval of the active substance mepiquat chloride in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council, and amending Commission Implementing Regulation (EU) No 540/2011Commission Implementing Regulation (EU) 2025/151 of 29 January 2025 concerning the renewal of the authorisation of a preparation of Levilactobacillus brevis DSM 21982 as a feed additive for all animal species and repealing Implementing Regulation (EU) No 838/2012Commission Implementing Regulation (EU) 2025/152 of 29 January 2025 concerning the authorisation of omicha tincture from Schisandra chinensis (Turcz.) Baill. and ginseng tincture from Panax ginseng C.A.Mey. as feed additives for certain animal speciesCommission Implementing Regulation (EU) 2025/153 of 29 January 2025 authorising the placing on the market of Lemna minor and Lemna gibba plants as novel food and amending Implementing Regulation (EU) 2017/2470Commission Implementing Regulation (EU) 2025/154 of 29 January 2025 concerning the authorisation of a preparation of Saccharomyces cerevisiae DSM 34246 as a feed additive for dogs and cats (holder of authorisation: ACEL pharma s.r.l.)Commission Implementing Regulation (EU) 2025/157 of 29 January 2025 concerning the authorisation of microcrystalline cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose and sodium carboxymethyl cellulose as feed additives for all animal speciesCommission Regulation (EU) 2025/158 of 29 January 2025 amending Annex II to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for acetamiprid in or on certain products
Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.
What to look at next
Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislationEU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and yearEuropean Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview